Explore News By Topic

10/24/2016

Genetic Counseling Center Dedicated To Advanced Prostate Cancer Opens In Seattle

Prostate cancer is one of the most heritable forms of cancer. Hereditary mutations in “DNA repair” genes – BRCA1, BRCA2, and others – which are best known for their association with breast and ovarian cancer predisposition, are now known to be associated with advanced prostate cancer. In fact, ~12% of... Read More

10/10/2016

Gene Identified that Drives Aggressive Prostate Cancer

An overactive gene appears to cause some prostate cancers to transform from a typical tumor type to a much more aggressive form of the disease, according to new research at Weill Cornell Medicine. The Prostate Cancer Foundation supported the study through a Janssen-PCF Challenge Award, which funds research conducted by... Read More

09/25/2016

Arnold Palmer

The Prostate Cancer Foundation celebrates the life and legacy of our friend, golf icon Arnold Palmer, who passed away on September 25, 2016. A legend in the truest sense of the word, he possessed a unique charisma that transcended his performance on the fairway. There is no question that Mr.... Read More

08/30/2016

The Prostate Cancer Foundation’s 2016 Coffey-Holden Prostate Cancer Academy Meeting Accelerates Advances In The Understanding And Treatment Of Metastatic Prostate Cancer

The Prostate Cancer Foundation (PCF) has a legacy of not only funding the most impactful research in prostate cancer, but also creating new infrastructures, global knowledge networks, and research initiatives that support and accelerate prostate cancer research towards better treatment for advanced prostate cancer patients. For the past four years,... Read More

08/09/2016

Asics Brings Out the Blue to Battle Against Prostate Cancer

October 28, 2014 -- ASICS America is again teaming up with the Prostate Cancer Foundation to expand their Accelerate Hope Collection™. Firmly committed to curing prostate cancer, the Prostate Cancer Foundation is the leading philanthropic organization funding and accelerating research for the disease globally. Featuring a variety of new ASICS... Read More

08/02/2016

2016 Movember Foundation – PCF Challenge Awards Fund Advances in Precision Treatment

Prostate Cancer Foundation Receives More Than $5 Million from the Movember Foundation 5 New Challenge Awards will Fund Investigations in Lethal Prostate Cancer SANTA MONICA, CA August 2, 2016 -- The Prostate Cancer Foundation (PCF) announces 5 new Movember Foundation-PCF Challenge Awards to advance new treatments and cures for metastatic,... Read More

Metastatic Prostate Cancer Cases Skyrocket Increase May Be Due To More Lax Screening Or More Aggressive Disease

Highest increase among men ages 55 to 69, who could benefit the most from screening and early treatment. Disease is more advanced when finally diagnosed. "Screening saves lives," urologists stress. "If I were a patient, I would want to be vigilant." Chicago -- The number of new cases of metastatic... Read More

07/15/2016

New study finds one in nine men with metastatic prostate cancer carry inherited mutations in DNA repair genes with important implications for treatment and for cancer risk in family members

https://vimeo.com/739319237/15d67dee4f Cancer, the uncontrolled growth of cells, is caused by the acquisition of genetic mutations that allow cells to evade the normal biological laws governing when and where they can grow in the body. Mechanisms that maintain the accuracy of our genomes are critical for preventing cells from collecting mutations... Read More

07/07/2016

INHERITED GENETIC MUTATIONS FOUND IN 12% OF MEN WITH METASTATIC PROSTATE CANCER

Mutations in 16 different DNA damage repair (DDR) genes have been identified as drivers of metastatic prostate cancer and other tumors, but are rare in the general population Approximately 12% of men with metastatic prostate cancer harbor inherited (germline) DDR mutations that likely caused their disease, even if they have... Read More

06/24/2016

A NEW GENOMIC CLASSIFIER ENABLES DIAGNOSIS OF THE AGGRESSIVE NEUROENDOCRINE SUBCLASS OF TREATMENT-RESISTANT PROSTATE CANCER

June 24, 2015 -- Tumor cells are continuously evolving to adapt to selective pressures introduced by changing host factors and the administration of new therapies. Following treatment with second-generation anti-androgen therapies abiraterone acetate (Zytiga®) and enzalutamide (Xtandi®), prostate tumors inevitably develop resistance and progress to lethal disease. Anti-androgen therapy-resistant prostate... Read More